Floating Button
Home News Healthcare

Medtecs upbeat vaccine won't hurt demand for PPE; gears up for direct to consumer sales

Lim Hui Jie
Lim Hui Jie • 8 min read
Medtecs upbeat vaccine won't hurt demand for PPE; gears up for direct to consumer sales
Will the Covid-19 vaccine put a halt to PPE maker Medtecs' meteoric rise? It's senior management doesn't think so.
Font Resizer
Share to Whatsapp
Share to Facebook
Share to LinkedIn
Scroll to top
Follow us on Facebook and join our Telegram channel for the latest updates.

Most companies’ price charts for 2020 would have shown a big plunge in March and April, as the fear over the pandemic infected the market. But the price chart of Taiwan-based Medtecs International stood out for its dramatically different pattern.

Precisely because of the pandemic, demand for personal protective equipment (PPE), which the company sells, enjoyed a huge surge — with both higher volumes and selling prices lifting Medtecs earnings and share price throughout the year.

For FY2020 ended December 2020, Medtecs reported revenue of US$400.3 million ($538.6 million), up 480.4% over FY2019. Thanks to better economies of scale and a higher proportion of higher-margin products, Medtecs’ earnings in the same period shot up by a whopping 11,196.4% to US$131.7 million, versus FY2019’s US$1.16 million.

×
The Edge Singapore
Download The Edge Singapore App
Google playApple store play
Keep updated
Follow our social media
© 2026 The Edge Publishing Pte Ltd. All rights reserved.